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Abstract
Objective—To report the changes in patient-reported quality of life for women undergoing 
gynecologic oncology surgeries.
Methods—In a prospective cohort study from 10/2013-10/2014, women were enrolled pre-
operatively and completed comprehensive interviews at baseline, 1, 3, and 6 months post-
operatively. Measures included the disease-specific Functional Assessment of Cancer Therapy-
General (FACT-GP), general Patient Reported Outcome Measure Information System (PROMIS) 
global health and validated measures of anxiety and depression. Bivariate statistics were used to 
analyze demographic groups and changes in mean scores over time.
Results—Of 231 patients completing baseline interviews, 185 (80%) completed 1-month, 170 
(74%) 3-month, and 174 (75%) 6-month interviews. Minimally invasive (n=115, 63%) and 
laparotomy (n=60, 32%) procedures were performed. Functional wellbeing (20 -> 17.6, p<.0001) 
decreased at 1-month, and recovered by 3 and 6 months. Emotional wellbeing increased (16.3 -> 
20.1, p<.0001) and anxiety decreased (54.2 -> 49.0, p<.0001) at 1-month, and were stable at 3 and 
6 months. Physical wellbeing scales were not sensitive to surgery. These patterns were consistent 
across procedure type, cancer diagnosis, and adjuvant therapy administration. In an exploratory 
analysis of the interaction of QOL and quality, patients with increased postoperative healthcare 
resource use were noted to have higher baseline levels of anxiety.
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Conclusions—For women undergoing gynecologic oncology procedures, temporary declines in 
functional wellbeing are balanced by improvements in emotional wellbeing and decreased anxiety 
symptoms after surgery. Not all commonly used QOL surveys are sensitive to changes during the 
perioperative period and may not be suitable for use in surgical quality metrics.
Introduction
Patient-reported outcome (PRO) measures, such as health related quality-of-life (HRQOL), 
are being increasingly incorporated into cancer care.1 Symptom monitoring with patient-
reported assessments decrease emergency room visits and hospitalizations, and are 
associated with improved health related quality-of-life in cancer patients.2 The National 
Quality Forum has begun to incorporate PROs into quality metrics.3 As this migration 
happens, serial PRO assessments, accounting for baseline, pre-treatment scores, will become 
increasingly important in research and clinical care.3
Surgery is a critical component of cancer care. In gynecologic oncology, it is often the first, 
if not only, part of cancer treatment. Serial assessment of health-related quality of life among 
gynecologic oncology patients is largely limited to populations participating in clinical 
trials.4–6 Often these assessments start after surgery, assigning ‘baseline’ quality of life to 
recently postoperative patients. In 2006, von Gruenigen et al reported on 42 women 
undergoing gynecologic oncology procedures with pre- and HRQOL post-operative data.7 
The pre and post-operative HRQOL scores came from different groups of patients however, 
which did not allow for continuous trend analysis from before to after surgery in the same 
patient.
In an environment focused on measuring quality of care through patient-reported quality of 
life, there is limited normative data on the quality of life journey of gynecologic oncology 
patients using validated survey instruments. The quality of life changes over the course of 
surgical treatment of non-clinical trial patients is unknown. The goal of this study was to 
document serial assessment of patient-reported health-related quality of life from before 
surgery to 6 months after surgery, for women undergoing gynecologic oncology procedures 
in a non-clinical trial setting. In addition, we present an example of anxiety and healthcare 
resource use to illustrate the potential interaction of patient-reported quality of life and a 
surgical quality metric.
Methods
Study Design, Enrollment, and Data Collection
We conducted a prospective longitudinal hospital-based cohort study of women enrolled in 
The Health Registry/Cancer Survivorship Cohort (HR/CSC) at the University of North 
Carolina. This was an Institutional Review Board approved study (#13-2367), for which all 
patients provided informed consent. For the HR/CSC, patients are identified and recruited 
through the UNC Health Care oncology outpatient clinics with the following eligibility 
criteria: age 18 years or older; North Carolina mailing address; and speak English or 
Spanish. Patients who are unable to provide informed consent or participate in interview 
questionnaires are excluded. For this study, eligibility was further restricted to HR/CSC 
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patients recruited through the gynecologic oncology clinics, with newly diagnosed 
gynecologic cancer and planned surgical management. Initial exclusion criteria included 
primary surgery completed or to be completed at an outside institution, previous 
chemotherapy or radiation therapy, and pregnancy. After the first 10 weeks of enrollment, 
the exclusion criteria was modified to allow for retention of patients with final benign 
pathology and those with prior, but not active, chemotherapy or radiation treatment. This 
was done to allow inclusion of women undergoing surgery for suspicious pelvic masses/
suspected ovarian cancer and patients with new recurrences.
Baseline interviews were conducted within 2 weeks of enrollment, prior to surgery, by 
trained staff using a computer-assisted telephone interview (CATI) software tool specifically 
developed for the HR/CSC. Follow-up interviews were conducted at 1, 3, and 6 months after 
surgery. Patients were included who completed follow-up interviews within a 3 week 
interval around each targeted time point (1 week prior or up to 2 weeks after the target date 
[e.g. 1, 3 or 6 months post-surgery]). Participants received gift cards as compensation after 
completion of each interview. Interview questionnaire topics included medical and social 
histories, and general and cancer-specific HRQOL assessments.
The following structured and validated questionnaires were included in this analysis: 
Functional Assessment of Cancer Therapy - General Population (FACT-GP),8 National 
Institute of Health Patient Reported Outcomes Measurement Information System 
(PROMIS©) global mental and physical health,9 PROMIS Anxiety,10 and PROMIS 
Depression.10 The FACT-GP version 4 is a 21-item scale that measures HRQOL using four 
subscales: physical, functional, emotional, and social wellbeing. The minimally important 
difference (MID) for the FACT-G is 5–7 points, and 2–3 points for each subscale. The 
PROMIS© v1.0 global is a 10-item scale that measures the domains of fatigue, physical 
function, pain, emotional distress, and social health. The PROMIS anxiety and depression 
measures11 are 4-item short form scales for each domain. PROMIS scales are scored using T 
scores, which are standardized to the U.S. general population and have a mean of 50 and a 
standard deviation of 10, and MIDs fall between 4 to 7 points. Scores above or below 50 are 
above or below the population average in the U.S., respectively.
Patient age, self-reported race/ethnicity, marital status, and employment status were 
abstracted from the HR/CSC baseline interview. The electronic medical record was reviewed 
to abstract clinical data at the time of new patient visit (BMI, co-morbid conditions, cancer 
site) and during the 30-day postoperative follow up window (surgical procedure, 
postoperative complications, and adjuvant treatment plan).
A composite variable of major medical comorbidity was created using the Charlson 
Comorbidity Index.12 Insurance status, at the time of new patient visit, was also abstracted 
from the medical record. The medical record information was then merged with the HR/CSC 
demographic and interview data.
Health care resource use (HCR) was defined as an unplanned clinic or emergency room 
(ER) encounter within 30 days after surgery. This definition excluded the standard post-
operative visit that is a part of every patient’s care, as well as any additional follow up that 
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was planned and noted at the time of hospital discharge. In an attempt to isolate those who 
sought additional care without an identifiable deviation from a normal postoperative course, 
we excluded patients who were subsequently diagnosed with a complication from one of 
these unplanned encounters.
Statistical Analysis
Summary statistics were generated using simple frequencies and percentages for categorical 
variables and mean with standard deviation for continuous variables. Mean scores of the 
FACT-GP and subscales, PROMIS global health measures, and PROMIS anxiety and 
depression measures were plotted. We used the paired t-test to compare change in mean 
scores over time (at 1, 3, and 6 months), as compared to baseline values. Although FACT 
score means have been commonly used to compare gynecologic oncology populations in 
observational and clinical trial studies4,7,13,14, as a sensitivity analysis, we also compared 
median scores using the Wilcoxon signed-rank test, with similar results. Graphs of mean 
score over time, stratified by different clinical groups, were constructed. Exploratory 
analysis of comparator groups of healthcare resource use was performed using student’s t-
tests accounting for unequal variance.
Results
Study Population
Of the 281 women who consented for the study, 231 completed baseline interviews, 187 
completed 1-month interviews, and 185 (80%) had completed medical record abstraction 
and are described in Table 1. A total of 170 (74%) completed the 3-month and 174 (75%) 
completed 6-month interviews (Supplemental Figure 1). Interview responders and non-
responders were assessed for differences in baseline characteristics. There was a greater 
proportion of ovarian cancer (39% vs 12%) and debulking procedures (26% vs 10%) in non-
responders. These differences were expected as ovarian cancer patients have the highest rate 
of complications and readmissions among gynecologic cancers, and thus may be the most 
difficult to follow for serial interview assessments. Responders and non-responders were 
balanced on all other characteristics (Supplemental Table A.1).
The baseline characteristics of the final analytic cohort are presented in Table 1. For the 
overall cohort, age at time of consent ranged from 22 to 93 years, with a median of 58 and 
interquartile range of 46 – 81. Due to small numbers, non-White and non-Black races were 
collapsed into an “Other” category, which included Asian (n=2, 1%), Native American (n=3, 
1.6%), and Other (n=5, 2.7%) respondents. There were 8 Hispanic women, 1 who identified 
as White, 1 as Black, and 5 as Other. There were 54 women with suspected malignancy who 
had benign disease on final pathology (49 with benign ovarian disease and 5 with vulvar 
dysplasia). BMI ranged from 17 to 58, with a median of 31.
Pre and Postoperative Trends in Health-Related Quality of Life
Different domains of health-related quality of life were affected differently by surgery. 
Overall mean FACT-GP score differed minimally at each time point assessment. There was a 
1 point change between baseline and 1-month mean scores. Final 6-month mean FACT-GP 
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scores were 3 points above baseline (Table 2). This lack of variation masks the actual 
changes that occurred within the FACT-GP subscales of functional and emotional wellbeing. 
Mean functional wellbeing scores decreased from 20.1 to 17.6 (p<.001) and mean emotional 
wellbeing scores increased from 16.3 to 20.3 (p<.0001) from baseline to 1 month post-
operatively. After 1 month, the functional and emotional well-being subscales remained 
nearly unchanged at the 3 and 6 month time points. For the social and physical wellbeing 
subscales, there were no significant differences at 1, 3, or 6 months (Figure 1).
The non-cancer specific, global quality of life scores of the PROMIS physical and mental 
health domains demonstrated minimal change over the 1, 3, and 6 month assessment points 
(Table 2, Supplemental Figure 2). The physical health scores were all slightly below 
population mean (50), which did not represent a clinical difference.
With regard to anxiety, overall, the cohort had a notably high baseline mean score on 
PROMIS Anxiety (54.1), which represented a clinically meaningful difference one-half 
standard deviation above population norms. This mean anxiety score decreased significantly 
1-month after surgery, from 54.1 preoperatively to 49.0 postoperatively (p<.001) (Table 2). 
Anxiety scores then remained near normal levels at 3 and 6 months. With regard to 
depression, although the PROMIS Depression scores were stable over 1, 3, and 6 month 
assessment points, they were nearly half a standard deviation higher than population norms. 
There were 41 women with PROMIS Depression scores over 60, representing a full standard 
deviation above population mean. Of note, only 1 of these women was noted to have a 
diagnosis of depression recorded in the medical record (Figure 2).
The cohort included different procedure types, women with final benign pathology, and 
those who did and did not require adjuvant therapy in the form of radiation or chemotherapy. 
We stratified the cohort by these groups to assess if the HRQOL trends differed by these 
factors. Although the baseline scores and the magnitude of change varied between groups, 
the overall trend of temporary functional wellbeing decline, alongside improvement of 
emotional wellbeing and decreased anxiety was consistent across all groups (Figure 3).
Exploratory Analysis: Anxiety and Healthcare Resource Use
This goal of this analysis was to explore a potential relationship between excess use of the 
healthcare system and a baseline patient-reported symptom, like anxiety. As stated in the 
methods, the healthcare resource use (HCR) variable was limited to patients with additional 
clinical encounters through the clinic or emergency room, which were unplanned, and did 
not result in any diagnosis of a complication. Patients were divided into HCR+ (n=14, 8%) 
and HCR- (n=171, 92%) users and mean anxiety scores compared over time. The HCR(+) 
group had higher baseline, pre-operative PROMIS Anxiety scores compared to HCR non-
users (58.3 vs 53.8, p=0.06), which quickly resumed to general population norms by 1 
month after surgery (Figure 4).
Discussion
The normal health-related quality of life journey for women undergoing gynecologic 
oncology procedures is nuanced. At the traditional time of post-operative assessment, 30 
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days or 1 month after surgery, decreases in functional wellbeing scores are balanced by 
increases in emotional wellbeing and decreases in anxiety. By 3 months, functional 
wellbeing returns to baseline levels, and emotional/anxiety improvements are maintained. 
The National Quality Forum has endorsed surgical PRO measures such as patient 
satisfaction and patient-reported trends in functional status after surgery for other surgical 
populations.15 The trends that we report from this study are important to the task of 
incorporating patient-reported outcome measures in the gynecologic oncology population, as 
the choice of scale or subscale, and the timing of assessment, will influence interpretation.
We found that disease-specific (FACT-GP) and general population (PROMIS global health) 
instruments perform differently in the perioperative period. The FACT scales are among the 
most commonly used disease-specific health related quality of life instruments in 
gynecologic oncology.3–5,13,16,17 The physical wellbeing scale of the FACT-GP did not 
register any change at the 1-month postoperative time point. This is due, in part, to the 
timing of our assessment. Abitbol et al reported on the FACT-G scores of 121 gynecologic 
oncology patients who underwent robotic procedures.13 This study included assessments at 
1 week and 3 weeks after surgery, and did find decrements in the physical wellbeing scale 
(−5.0 points) at the 1 week mark, that normalized by 3 weeks. This study was limited by 
high attrition rate, with 37% non-response at 1 week and 52% non-response by 3 weeks. In 
contrast to our work, the study by Abitbol et al did demonstrate some change in the physical 
wellbeing scale at 1 week. One week after surgery is far sooner than the average 4–6 week 
recovery time expected for most major gynecologic oncology procedures. Although valuable 
information can be gained from immediate post-operative PRO data, we propose that 
national level quality measures would most meaningfully be assessed at a time point when 
the majority of patients are expected to have recovered. This allows for identification of true 
outliers. For example, substantial differences in patient-reported quality of life at 1 month 
after surgery between surgeons, procedure types, or hospital systems, would be more likely 
to highlight systematic underlying quality differences that warrant process reviews and 
potential penalties. In that context, the physical wellbeing subscale, a seemingly appropriate 
‘physical’ indicator of quality of life, may not best provide information as to different patient 
experiences based on surgical quality. In contrast, more immediate (e.g. 1 week) PRO 
measures may be more appropriate on a small scale, like an in-hospital quality improvement 
initiative, to fine tune perioperative processes.
In contrast, the functional wellbeing subscale was reactive to surgery, with a clinically 
meaningful decrease at 1 month post-operatively with resumption to baseline by 3 months. 
This could be used as a patient-centered benchmark of routine surgical recovery: the 
resumption of baseline patient-reported functional status by 30 to 60 days post-operatively, 
for example.
Another aspect to consider when choosing a PRO instrument, is that just having a score 
change does not make a PRO suitable as a quality measure. Our findings of increased 
emotional wellbeing and decreased anxiety are examples. These “improvements” likely 
reflect the abnormally heightened fear and anxiety preoperative patients can feel when 
facing the unknown experience of major surgery and unclear diagnosis. The improvement in 
emotional quality of life and anxiety likely reflect resolution of the feared unknown. This is 
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supported by the fact that the baseline values for these two domains were worse (higher 
anxiety, lower emotional wellbeing) than the general population and the changes seen 
represent a recovery back to normal. Using either of these measures as a surrogate patient-
reported assessment of quality, may falsely assign value to a normal change based only on 
having had a procedure.
Another lens into the use of patient-reported outcomes for surgical quality measures is in 
risk-adjustment. Our exploratory analysis of anxiety and health care resource is use is very 
limited and not meant to be conclusive. It is however an interesting example of how patient 
factors that currently go unmeasured, like preoperative anxiety, may very well have effects 
on quality measures, like unplanned emergency room encounters without a diagnosis of 
complication. Anxiety is known to affect medical decision making18 in other areas of cancer 
care. It is reasonable to consider that heightened anxiety may lead to the need for clinical 
reassurance in a patient having a routine recovery. Just as we risk-adjust our complication 
rates, to account for obesity, diabetes, and other major contributors to increased 
complication, baseline patient-reported outcomes can expand our ability to adjust for 
previously ‘intangible’ patient factors that lead to increased resource use.
Finally, although the point has been well made in other publications,19–21 we want to 
emphasize the discrepancy between patient-reported anxiety and depression levels, and the 
limited notation of such in the medical record. Patient reported outcomes have the power, 
right now, to better inform us of the physical and mental wellbeing of our patients. They can 
be currently embraced as a way to improve all aspects of care for each and every patient in 
gynecologic oncology.
Our study has important limitations to note. It is a single-institution study and therefore the 
results may not be generalizable on a broader scale. Unlike clinical trials, the proportion of 
Black women (17%) in our study was actually representative of the larger state population 
(22%),22 however, we had under-representation of Hispanic women (3.4%) compared to the 
state (8%).22 This may in part be due to the relatively young median age of Hispanics in the 
state (33 years)23 compared to the median age of gynecologic oncology patients (49 – 68 
years).24 We also had an over-representation of patients with private insurance (84%) 
compared to the state population of women > 18 years (68%).22 Our first postoperative 
assessment was at 1-month and each interview asked the patient to recall experiences over 
the past 7 days. This schedule may have missed early 1–3 week experiences in surgical 
recovery, although as noted above, this 1 month time point may be more appropriate when 
considering surgical quality metrics. In addition, we included multiple different procedure 
types that may inherently affect quality of life differently. We did, however, use the same 
scales used in surgical randomized trials, where these scores were not found to differ by 
procedure type such as laparoscopy versus laparotomy or sphincter-sparing surgery versus 
abdominoperineal repair.4,25 Within the cancer patients, trends in HRQOL may have varied 
by confirmed versus suspected cancer diagnoses prior to surgery. For those patients without 
a definitive pre-operative cancer diagnosis, we did not have preoperative information 
regarding perceived risk of cancer by the patient and/or provider to address this question.
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Our study has many unique strengths. We had a high response rate (>80%) at each 
assessment interval through the 6-month interviews, adding robustness to the follow up data. 
The interviews were performed by independent, trained administrators in person or over the 
phone, limiting bias with literacy skills. Additionally, assessments included multiple aspects 
of health-related quality of life including depression and anxiety. This analysis highlights the 
need for more longitudinal studies of different, and potentially newly developed, HRQOL 
instruments to ensure we have the most informed and valuable patient-reported outcome 
measures for gynecologic oncology patients.
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Highlights
• Temporary declines in functional wellbeing are balanced by 
improvements in emotional wellbeing and anxiety at 1 month post-
operatively.
• Current commonly used health-related quality of life instruments may 
not best reflect the perioperative surgical experience.
• Increased patient-reported baseline anxiety may be associated with 
increased post-operative healthcare resource use.
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Figure 1. 
The subdomains of the Functional Assessment of Cancer Therapy-General for all women 
undergoing gynecologic oncology procedures. Physical and Social domains were minimally 
responsive to surgery. Functional wellbeing declined at 1 month and recovered. Emotional 
wellbeing began at low levels and increased to normal levels after surgery. The changes in 
functional and emotional wellbeing represent changes larger than the minimally important 
differences (MID) for each scale.
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Figure 2. 
Mean scores on PROMIS Anxiety 4-s and PROMIS Depression 4-s surveys, from baseline 
to 6 months post-operatively for women undergoing gynecologic oncology procedures. A 
score of 50 represents mean normal value of the general population.
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Figure 3. 
The main trends of functional wellbeing, emotional wellbeing, and anxiety were stratified by 
major clinical characteristics: procedure type (MIS [n=115] vs. Laparotomy [n=60]), final 
pathology (Cancer [n=131] vs. Benign [n=54]), and the need for adjuvant therapy within the 
cancer group (Yes [n=77] vs. No [n=54]). Although baseline values and magnitude of 
changes differed, the trend directions were the same.
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Figure 4. 
There were 15 HCR (+) users, 10 clinic visits and 5 ER visits. The HCR(+) group had 
higher baseline, pre-operative PROMIS Anxiety scores compared to HCR non-users (58.2 vs 
53.8, p=0.06).
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Table 1
Cohort Characteristics of Women Undergoing Gynecologic Oncology Surgerya
Characteristics
Overall
N = 185
Age, mean (SD) 56.5 (13)
Race
White 143 (77)
Black 32 (17)
Other 10 (5)
Cancer Site
Uterine 84 (45)
Ovary 23 (12)
Cervix 17 (9)
Vulva/Vaginal 3 (1.6)
Otherb 4 (2)
Benign 54 (29)
Insurance
None 14 (8)
Medicare Only 8 (4)
Medicaid 7 (4)
Any Private 156 (84)
Marital Status
Partnered 114 (62)
Single 51 (28)
Widowed 20 (11)
Employment
No 98 (53)
Yes 87 (47)
Charlson Comorbidity Index
0 117 (63)
1 48 (26)
2+ 20 (11)
BMI, mean(SD) 32.9 (SD 9)
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Characteristics
Overall
N = 185
Procedure Typec
MISd 116 (63)
Laparotomy 60 (32)
Debulking 20 (10)
Radical Hysterectomy 13 (7)
Bowel surgery 12 (7)
Groin Surgery 8 (4)
Adjuvant Therapyd Yes 77 (42)
No 55 (30)
NAe 54 (29)
aAll data presented as No. (%) unless otherwise noted.
bOther includes: 1 patient with gynecologic malignancy, unknown primary and 3 patients with final pathology of gastro-intestinal origin.
c
These are non-exclusive categories of procedures performed and therefore do not add up to 100%. MIS: Minimally invasive surgery, including 
traditional and robotic-assisted laparoscopy.
d
Including chemotherapy, radiation, or hormonal therapy.
NA: not applicable, refers to benign disease patients.
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Table 2
Health-Related Quality of Life Over Time: from Preoperative Baseline to 6-Months After Surgery for Entire 
Cohorta
Survey Instrument
Baseline
N=185
1-Month
N=185
3-Month
n=170
6-Month
n=174
FACT-GP 82 (19) 83 (18) 85 (19) 85 (18)
 Physical 23 (5) 22 (5) 22 (6) 23 (5)
 Functional 20 (7) 18 (7)b 20 (7) 20 (7)
 Emotional 16 (6) 20 (5)b 20 (5)b 21 (5)b
 Social 23 (6) 23 (5) 22 (6) 22 (6)
PROMIS Global Health
 Physical 47 (8) 46 (7) 47 (10) 48 (10)
 Mental 50 (8) 51 (8) 51 (9) 51 (10)
PROMIS Anxiety 54 (9) 49 (9)b 49 (9)b 48 (8)b
PROMIS Depression 54 (7) 53 (6) 54 (6) 54 (7)
aAll scores represented as mean(SD).
b
Indicates p <.05 for paired t-test comparing baseline mean score to follow up score.
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